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OBJECTIVE — Offspring of mothers with impaired glucose tolerance are far more likely to
develop type 2 diabetes. We tested the hypothesis that maternal glucose tolerance in pregnancy
affects fetal insulin sensitivity or -cell function.
RESEARCH DESIGN AND METHODS — In a prospective singleton pregnancy cohort
study,weanalyzedglucose,insulin,andproinsulinconcentrationsinmaternalbloodatthe50-g
oral glucose tolerance test (OGTT) at 24–28 weeks of gestation and in venous cord blood (n 
248). The cord blood glucose-to-insulin ratio and proinsulin concentration were used as indi-
cators of fetal insulin sensitivity and the proinsulin-to-insulin ratio was used as an indicator of
fetal -cell function.
RESULTS — HigherOGTTbloodglucoselevelswereassociatedwithsigniﬁcantlylowercord
plasma glucose-to-insulin ratios (r  0.31, P  0.001) and higher proinsulin concentrations
(r  0.31, P  0.001) but not with proinsulin-to-insulin ratios. In a comparison of gestational
diabetic (n  26) versus euglycemic pregnancy, cord blood glucose-to-insulin ratios were sub-
stantially lower (geometric mean 10.1 vs. 20.0 mg/dl/U/ml; P  0.001), whereas proinsulin
concentrations were much higher (24.4 vs. 13.8 pmol/l; P  0.001), despite similar cord blood
glucose concentrations indicating adequate management of diabetes. The differences remained
signiﬁcant after controlling for prepregnancy and fetal adiposity, family history of diabetes,
gestational age, and other potential confounders. Signiﬁcant changes in the glucose-to-insulin
ratio and proinsulin concentration were also observed in obese (n  31) mothers, but the
differences became not statistically signiﬁcant after adjustment for maternal glucose tolerance
and fetal adiposity.
CONCLUSIONS — Maternal glucose intolerance may impair fetal insulin sensitivity (but
not -cell function) and consequently “program” the susceptibility to type 2 diabetes.
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T
he metabolic syndrome and type 2
diabetes have become a worldwide
epidemic of concern (1,2). The
rapid rise of the epidemic over recent de-
cades points to the predominant role of
preventable “environmental” inﬂuences.
The question is, what factors at what time
points are critically important targets for
effective interventions? There is an in-
creasing recognition that the fetal envi-
ronment may “program” susceptibility to
the metabolic syndrome and related dis-
orders(3,4).Thissuggestsanopportunity
for early interventions to halt the increas-
ing occurrence of the metabolic syn-
drome if we could know more about the
targetsandmechanismsofmetabolicpro-
gramming in early life.
Maternal metabolic status affects the
fetal environment and plausibly has the
potential to program the metabolic func-
tion axis of the offspring during critical
developmental stages through various
mechanisms (e.g., epigenetic changes)
(5). Indeed, independent of the type of
diabetes (pregestational type 1 or type 2
or gestational), offspring of diabetic
mothers are far more likely to develop
metabolic syndrome and type 2 diabetes
(6–10).Mostcases(90%)ofdiabetesin
pregnancy are gestational diabetes melli-
tus (11). Mild gestational glucose intoler-
ance not meeting the criteria for the
diagnosis of gestational diabetes mellitus
has also been associated with adverse
pregnancy outcomes and elevated cord
blood C-peptide levels (12). Obesity is
closely associated with impaired glucose
tolerance (2,13), and, recently, increased
insulin resistance was observed among
neonates of obese mothers (14). Taken
together, these observations suggest that
impaired glucose tolerance in pregnancy
may program the propensity to develop-
ment of the metabolic syndrome. How-
ever, there is a dearth of prospective
pregnancy cohort data to demonstrate
what metabolic parameters are pro-
grammed in utero. We aimed to test the
hypothesis that maternal glucose toler-
ance in pregnancy affects fetal insulin
sensitivity or -cell function. Such a rela-
tionship may underlie the long-term pre-
disposition to the metabolic syndrome
and related disorders in offspring of dia-
betic mothers.
RESEARCH DESIGN AND
METHODS— We conducted a pro-
spective pregnancy cohort study. Patients
were recruited from three obstetric care
centers in Montreal: Sainte-Justine, Jew-
ish General, and Saint Mary’s Hospital.
The study was approved by the research
ethics committees of the participating
hospitals. Pregnant women bearing a sin-
gleton fetus were recruited at 24–28
weeks of gestation upon signing an in-
formed consent form. Exclusion criteria
were1)multiplepregnancy;2)illicitdrug
use;3)maternalage18or45years;4)
severepreexistingillnessesincludingpre-
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pertension,renalfailure,activeorchronic
liver diseases, epilepsy, collagen disor-
ders, serious pulmonary disease, serious
hematological disorders, cancer, heart
disease, or other life-threatening condi-
tions; 5) endocrine disorders including
growth hormone deﬁciency, hyperthy-
roidism, hypothyroidism, or other
known endocrine disorders; and 6)
known congenital anomalies or chromo-
somalabnormalitiesinthefetus.Atotalof
339patients(25%)of1,333eligiblepreg-
nant women approached for recruitment
accepted to participate between August
2006 and December 2008, and 248
mother-infant pairs (73% patients) with
complete data on all studied biomarkers
in maternal and cord blood specimens
constituted the ﬁnal study cohort.
There were no signiﬁcant differences in
maternalcharacteristics between patients
included versus those excluded in the
present study. There were 11 preterm
births, all mild preterm (33–36 weeks).
Excluding such preterm births did not af-
fect any primary results; thus, they were
retained in the study.
Inallthethreeparticipatinghospitals,
pregnantwomenwereroutinelytestedfor
a random blood glucose level in the ﬁrst
trimester (6–13 weeks) of pregnancy to
screen for undiagnosed pregestational di-
abetes mellitus. A random blood glucose
value 7.8 mmol/l (140 mg/dl) was con-
sidered abnormal for further screening
tests.Allrecruitedpatientshadvaluesless
than this cutoff.
Data and specimen collection
Data and specimens were collected at
24–28 and 32–35 weeks of gestation and
at delivery. Trained research nurses and
assistants collected data on maternal,
pregnancy,andbirthcharacteristicsusing
structured study questionnaires through
face-to-face interviews and medical chart
reviews. Maternal prepregnancy weight
(kilograms) was based on self-report. Ma-
ternal height was measured to the nearest
centimeter using the routinely available
stadiometer and weight before delivery to
the nearest 0.1 kg using the routinely
available weighing device in each hospi-
tal. Prepregnancy BMI (weight in kilo-
grams divided by the square of height in
meters) was calculated as an indicator of
maternaladiposity.Birthweightwasmea-
sured to the nearest gram using the rou-
tinely available electronic weighing
device in each delivery unit. Birth length
was measured to the nearest 0.1 cm using
the 447 Infantronic Digital Infantometer
(QuickMedical, Seattle, WA) purchased
for all participating hospitals. Ponderal
index (kilograms per cubic meter) was
calculated as an indicator of fetal
adiposity.
Maternal blood specimens were col-
lected at 24–28 weeks of gestation at the
time of the routine prenatal 50-g 1-h oral
glucose tolerance test (OGTT) to screen
for gestational diabetes mellitus and at
32–35 weeks of gestation (random
blood). Venous cord blood specimens
were collected immediately after the de-
liveryofthebabybutbeforetheexpulsion
of the placenta. For cesarean section de-
liveries, venous cord blood samples were
taken immediately after removal of the
placenta. Research assistants were avail-
able24-hon-callfortimelycollectionand
processing of cord blood specimens. All
specimens collected were kept on ice and
stored temporarily in a 4°C refrigerator
and centrifuged within 30 min after spec-
imen collection. The separated plasma
samples were stored in multiple aliquots
in a freezer at 80°C until assays.
Impaired glucose tolerance and
gestational diabetes mellitus
Impaired glucose tolerance (n  31) was
deﬁned as blood glucose concentration
7.8 mmol/l (140 mg/dl) in the 1-h 50-g
OGTT at 24–28 weeks of gestation but
did not meet the criteria for the diagnosis
of gestational diabetes mellitus. If the
50-g OGTT blood glucose concentration
was between 7.8 and 11.1 mmol/l, the
woman underwent the diagnostic 2-h
75-gOGTT.Gestationaldiabetesmellitus
was diagnosed if the woman had two of
three values exceeding the following cut-
offs for fasting glucose: 5.3 mmol/l, 1-h
10.0 mmol/l, or 2-h 8.6 mmol/l (Ameri-
can Diabetes Association criteria) (15). If
the 50-g OGTT blood glucose concentra-
tion was 11.1 mmol/l (200 mg/dl), a
diagnosis of gestational diabetes mellitus
was made without further tests. Gesta-
tional diabetes mellitus (n  26) was well
managed in participating hospitals by di-
etary and lifestyle interventions and insu-
lin treatment if required to achieve
euglycemia. Patients who had insulin
treatment were not excluded because in-
sulin does not pass the placenta barriers
and the treatment did not affect primary
outcome indicators among our patients
with gestational diabetes mellitus.
Biochemical assays
Maternal blood glucose concentrations
(millimoles per liter and milligrams per
deciliter) in the ﬁrst trimester random
blood and 50-g OGTT blood samples at
24–28 weeks of gestation were taken
fromroutineprenatalclinicaltestrecords.
Blood glucose concentrations were deter-
mined by the same glucose oxidase
method in the certiﬁed clinical biochem-
istry laboratories of all participating hos-
pitals. Cord blood plasma glucose
concentrations were determined in the
biochemistry laboratory of Sainte-Justine
Hospital,usingtheautomatedglucoseox-
idase method (Beckman-Coulter, Brea,
CA). Intra- and inter-assay coefﬁcients of
variation were 2 and 3%, respectively.
Plasma insulin (picomoles per liter
and microunits per milliliter) and proin-
sulin (picomoles per liter) concentrations
were determined in maternal OGTT
blood at 24–28 weeks, in maternal ran-
dom blood at 32–35 weeks, and in cord
blood in the same laboratory at Sainte-
Justine Hospital. Plasma insulin was mea-
sured by an automated ultrasensitive
chemiluminescent immunometric assay
(Beckman-Coulter). The intra-assay and
interassay coefﬁcients of variation were 2
and 6%, respectively. Cross-reactivity
was 0.3% with proinsulin, and none with
C-peptide. Plasma proinsulin was mea-
suredbyaquantitativeELISAkit(ALPCO
Diagnostics, Salem, OR). The intra-assay
and interassay coefﬁcients of variation
were 3 and 5%, respectively. Cross-
reactivity was 0.1% with human insulin
and 0.01% with C-peptide.
Primary outcomes
The cord plasma glucose (milligrams per
deciliter)-to-insulin (microunits per mil-
liliter) ratio was used as the primary indi-
cator of fetal insulin sensitivity (16,17);
other indicators include cord plasma in-
sulin and proinsulin concentrations.
Cord blood proinsulin-to-insulin ratio
was used as a surrogate indicator of -cell
function (18,19). Maternal fasting was
not requested for the delivery visit.
Statistical analysis
MeansSDarepresentedforcontinuous
variables. Geometric means are presented
for biomarkers with skewed crude data
distribution (insulin, proinsulin, glucose-
to-insulinratio,andproinsulin-to-insulin
ratio).Logtransformationwasappliedfor
variableswithskeweddatadistributionin
allcomparisons.Pearsoncorrelationanal-
ysis was used to assess the association
Fetal insulin sensitivity
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correlation analysis was used to assess the
association controlling for other continu-
ous variables. Generalized linear regres-
sion analyses were conducted to assess
the associations controlling for multiple
covariables (categorical and continuous).
The covariables included maternal glu-
cose tolerance (normal, impaired, and
gestational diabetes mellitus; per SD in-
crease in the 50-g OGTT glucose concen-
tration), prepregnancy BMI (BMI 30
kg/m
2 obese, 25.0–29.9 kg/m
2 over-
weight, and 25.0 kg/m
2 normal weight;
per SD increase), maternal ethnicity
(French mother tongue, the majority
group in Quebec, and others), family his-
tory of diabetes (yes or no, among ﬁrst-
degree relatives), maternal age (35 or
35 years), parity (primiparous: yes or
no), smoking (yes or no), alcohol use (yes
or no), gestational hypertensive compli-
cations (yes or no), bacterial vaginosis or
other minor infections (yes or no) (no pa-
tients had any major infections requiring
hospitalization or emergency care), glu-
cose intravenous administration during
delivery (yes or no), mode of delivery (ce-
sarean or vaginal), infant sex, gestational
age (weeks), birth weight (SD score,
basedonCanadianfetalgrowthstandards
[20]), and ponderal index (per SD in-
crease). All data management and analy-
ses were conducted using SAS (version
9.0; SAS Institute, Cary, NC). Two-tailed
P  0.05 was considered statistically
signiﬁcant.
RESULTS
Maternal and pregnancy
characteristics
Comparing patients with impaired glucose
tolerance and gestational diabetes mellitus
withthosewithaeuglycemicpregnancy,we
foundnosigniﬁcantdifferencesinmaternal
age, ethnicity, smoking, prepregnancy
weight, weight gain in pregnancy, and rates
of gestational hypertensive complications,
bacterial vaginosis and other minor infec-
tions, and intravenous glucose administra-
tionduringdelivery(Table1).Patientswith
impaired glucose tolerance and gestational
diabetes mellitus were less likely to be pri-
miparous (28 vs. 44%), were shorter in
height (mean 162.8 vs. 164.9 cm), had a
higherprepregnancyBMI(25.3vs.23.4kg/
m
2), and were more likely to have taken
alcohol during pregnancy (26 vs. 10%) or
have a family history of diabetes (28 vs.
16%). Their infants were born slightly ear-
lier (mean gestational age 38.5 vs. 39.1
weeks) and had similar birth weight, birth
length, and ponderal index. About half of
the women were given intravenous glucose
during delivery; they were retained in all
analysesbecausetheglucoseadministration
did not affect the primary outcomes, cord
blood glucose-to-insulin ratio (P  0.2),
proinsulin-to-insulin ratio, and proinsulin
concentration (all P  0.9).
Correlations between maternal and
fetal metabolic parameters
Higher 50-g OGTT glucose concentra-
tions (lower glucose tolerance) were
strongly correlated with higher cord
plasma insulin (r  0.30; P  0.001) and
proinsulin (r  0.31; P  0.001) concen-
trations and lower glucose-to-insulin ratios
(r  0.31; P  0.001) but were not cor-
related with proinsulin-to-insulin ratios in
cord blood. First trimester random blood
glucose levels were positively correlated
with cord blood proinsulin concentrations
(r  0.17; P  0.01). Cord plasma proin-
sulin concentrations were strongly posi-
tively correlated with maternal plasma
proinsulin concentrations at both 24–28
(r  0.37; P  0.001) and 32–25 weeks
(r  0.32; P  0.001) of gestation.
Partial correlation analyses revealed
that maternal glucose tolerance (OGTT
glucose level), prepregnancy adiposity
(BMI), and fetal adiposity (ponderal in-
dex) were all negatively associated with
Table 1—Maternal, pregnancy, and neonatal characteristics and metabolic parameters in a
prospective singleton pregnancy cohort study
All subjects
Normal glucose
tolerance
Impaired glucose
tolerance and gestational
diabetes mellitus
n 248 191 57
Mother
Ethnicity: French Canadians 112 (45.1) 88 (46.1) 24 (42.1)
Age (years) 31  4.7 30.8  4.7 31.7  4.7
35 57 (23.0) 43 (22.5) 14 (24.6)
Primiparous 100 (40.3) 84 (44.0) 16 (28.1)§
Tobacco smoking (yes/no) (%) 18 (7.3) 15 (7.9) 3 (5.3)
Drinking alcohol (yes/no) (%) 34 (13.7) 19 (10.0) 15 (26.3)
Family history of diabetes (%) 47 (19.0) 31 (16.2) 16 (28.1)§
Height (cm) 164.1  6.4 164.9  6.3 162.8  6.4§
Pregnancy
Prepregnancy weight (kg) 64.5  14.1 63.8  13.2 67.2  16.6
Prepregnancy BMI (kg/m
2) 23.9  5.0 23.4  4.6 25.3  5.9§
Gestational age at recruitment
(weeks) 25.7  1.1 25.8  1.1 25.6  1.1
Weight gain in pregnancy (kg) 15.7  5.7 16.0  5.5 14.9  6.2
Gestational hypertension 14 (5.7) 13 (6.8) 1 (1.8)
Vaginosis or other minor
infections* 39 (15.7) 30 (15.7) 9 (15.8)
Glucose intravenously at
delivery† 119 (48.4) 91 (47.9) 28 (50.0)
Cesarean section 70 (28.5) 47 (24.7) 23 (41.1)§
Baby
Sex (boy) 133 (53.9) 102 (53.7) 31 (54.4)
Gestational age (weeks) 39.0  1.5 39.1  1.4 38.5  1.7§
Birth weight (g) 3,444  445 3,447  432 3,438  489
Birth length (cm) 50.6  2.1 50.7  2.1 50.3  2.1
Ponderal index (kg/m
3) 26.6  2.8 26.4  2.8 27.0  3.0
Birth weight z score‡ 0.1  0.9 0.1  0.9 0.3  1.1
Preterm birth (37 weeks) 11 (4.4) 6 (3.1) 5 (8.8)
DataaremeansSDforcontinuousvariablesandn(%)forfrequencyvariables.n248.*Minorinfections
refer to any treatment for infections during pregnancy. No patients had any “major” infections requiring
hospitalizationsoremergencycare.†Patientswhoweregivenglucoseintravenouslyduringthedelivery(5%
dextroseinallsuchcases).‡Basedonsex-andgestationalage–speciﬁcCanadianfetalgrowthstandards.§P
0.05; P  0.01 in tests for differences comparing women with impaired glucose intolerance and gestational
diabetes mellitus to those with normal glucose tolerance.
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the mutual adjustments, the correlation
coefﬁcients changed little for maternal
glucose tolerance (crude r  0.31, par-
tialr0.29,P0.001),butdecreased
substantially for prepregnancy adiposity
(cruder0.21,partialr0.16,P
0.01) and decreased for fetal adiposity
(cruder0.21,partialr0.19,P
0.003). Similarly, a stronger correlation
with fetal proinsulin concentration was
observed for maternal glucose tolerance
(crude r  0.31, partial r  0.30, P 
0.001) than for prepregnancy adiposity
(crude r  0.19, partial r  0.12, P 
0.05) or fetal adiposity (crude r  0.24,
partial r  0.23, P  0.001). Similar cor-
relations were observed in boys and girls
(data not shown).
Differences in fetal metabolic
parameters by maternal glucose
tolerance
As expected, glucose, insulin, and pro-
insulin concentrations at the OGTT
were substantially higher in patients
with impaired glucose tolerance and
even more so in those with gestational
diabetes compared with euglycemic
pregnancy (Table 2). However, there
were no signiﬁcant differences in cord
blood glucose concentrations and pro-
insulin-to-insulin ratios among the
three study groups. From euglycemia to
impaired glucose tolerance to gesta-
tional diabetes mellitus, ﬁrst trimester
random blood glucose levels trended
marginally higher (P  0.05), whereas
cord blood glucose-to-insulin ratios
trended signiﬁcantly lower, and insulin
and proinsulin concentrations trended
signiﬁcantly higher (P  0.001).
Marked changes in cord blood meta-
bolic biomarkers were observed in pa-
tientswithgestationaldiabetesmellitus,
whereas the changes were much milder
in patients with impaired glucose toler-
ance not meeting the criteria for the di-
agnosis of gestational diabetes mellitus.
The marked changes in cord blood met-
abolic parameters (insulin, proinsulin,
and glucose-to-insulin ratio) among pa-
tients with gestational diabetes mellitus
remained signiﬁcant after adjustment
for maternal smoking, alcohol use,
prepregnancy adiposity (BMI), family
history of diabetes, gestational age,
ponderal index, and other potential
confounders. Thedifferences were similar
andremainedsigniﬁcantinsubgroupswith
(n  119) and without (n  129) maternal
intravenous glucose administration during
delivery (data not shown). Among patients
with gestational diabetes mellitus (n  26),
insulintreatment(n17)didnotaffectthe
primary outcomes, cord blood glucose-to-
insulin ratio (P  0.4), proinsulin-to-
insulin ratio (P  0.6), and proinsulin
concentration (P0.5). Therefore, the ob-
served differences in the primary outcomes
comparing gestational diabetic versus eu-
glycemic pregnancies should be attribut-
able to diabetes rather than to the insulin
treatment.
Table 2—Maternal and fetal metabolic parameters comparing women with normal glucose tolerance, impaired glucose tolerance, and
gestational diabetes mellitus
Normal glucose
tolerance
Impaired glucose
tolerance
Gestational
diabetes mellitus
P value for difference
trend
Adjusted
P value*
n 191 31 26
Mother in pregnancy
First trimester, random blood
Glucose (mg/dl) 83.4  14.1 85.2  12.5 90.4  15.9 0.13 0.05 0.48
Glucose (mmol/l) 4.6  0.8 4.7  0.7 5.0  0.9
24–28 weeks, 50 g OGTT
Glucose (mg/dl) 105.6  17.9 152.8  12.7‡ 170.4  28.8§ 0.0001 0.0001 0.0001
Glucose (mmol/l) 5.9  1.0 8.5  0.7 9.5  1.6
Insulin (mU/ml) 39.4  53.6 69.3  69.0‡ 93.0  76.6§ 0.0001 0.0001 0.0001
Insulin (pmol/l) 236.5  321.5 415.6  414.0 557.9  459.5§
Proinsulin (pmol/l) 17.5  10.9 21.3  15.6 27.3  21.3‡ 0.0001 0.001 0.003
Proinsulin-to-insulin ratio 0.07  0.08 0.05  0.04 0.05  0.05 0.20 0.12 0.11
32–35 weeks, random blood
Proinsulin (pmol/l) 16.6  13.4 20.3  18.5 17.8  23.4 0.30 0.28 0.47
Fetus (cord blood)
Glucose (mg/dl) 84.7  17.4 78.7  11.1 81.1  16.7 0.12 0.13 0.12
Glucose (mmol/l) 4.6  1.0 4.4  0.6 4.5  0.9
Insulin (mU/ml) 4.1  4.8 4.3  3.2 7.8  8.2† 0.001 0.001 0.02
Insulin (pmol/l) 24.8  28.6 25.7  19.1 47.0  49.2†
Glucose (mg/dl)-to-insulin (U/ml) ratio 20.0  24.2 18.2  14.5 10.1  10.0† 0.001 0.001 0.03
Proinsulin (pmol/l) 13.8  9.4 14.9  8.7 24.4  15.8§ 0.0001 0.0001 0.0001
Proinsulin-to-insulin ratio 0.56  0.59 0.58  0.44 0.52  0.42 0.84 0.76 0.40
Data are means  SD unless otherwise indicated. Geometric means are presented for biomarkers (insulin, proinsulin, glucose-to-insulin ratio, and proinsulin-to-
insulin ratio) with highly skewed crude data distributions. Pseudo-SDs (in regular scale) are presented for geometric means by calculating the average SDs within
the 95% CIs (1 SD change is not a constant in back-transformation from the log to regular scale, larger in the upper tail). 50 g OGTT  50 g, 1-h OGTT. *Adjusted
P values for the differences across the three study groups. For maternal measurements, the comparisons were adjusted for ethnicity, age, parity, smoking, alcohol
use,andprepregnancyBMI(SDscore);forcordbloodmeasurements,thecomparisonswerefurtheradjustedforfamilyhistoryofdiabetes,weightgaininpregnancy
(SDscore),gestationalhypertension,bacterialvaginosisandotherminorinfections(nomajorinfectionsreported),modeofdelivery,maternalglucose(5%dextrose,
in all such cases) infusion during delivery, infant sex, gestational age, birth weight (SD score), and ponderal index (SD score). †P  0.05; ‡P  0.01; §P  0.001,
for comparisons to the reference group (normal glucose tolerance) after the adjustments; similar differences were observed in boys and girls (data not shown). The
same unit (picomoles per liter) was used for both insulin and proinsulin in calculating the proinsulin-to-insulin ratio.
Fetal insulin sensitivity
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Infants of obese (n  31) mothers had
lower cord plasma glucose-to-insulin ra-
tios (geometric mean 13.0 vs. 20.5 for
normal-weight mothers; crude P 
0.004, adjusted P  0.20) and higher in-
sulin (6.1 vs. 4.1 U/ml; crude P 
0.007, adjusted P  0.12) and proinsulin
(18.7 vs. 13.9 pmol/l, crude P  0.008,
adjusted P  0.16) concentrations, but
those differences became not statistically
signiﬁcant after adjustment for maternal
glucose tolerance and fetal ponderal in-
dexalone.Bothcrudeandadjusteddiffer-
ences in these biomarkers were not
statistically signiﬁcant, comparing infants
of overweight (n  48) versus normal-
weight mothers.
Effects per SD change
The effect estimates per SD change in
multivariate regression analyses showed
that maternal glucose tolerance had the
greatest impact on cord plasma glucose-
to-insulinratioandproinsulinconcentra-
tion(Table3).Theeffectsizeformaternal
glucose tolerance on the fetal glucose-to-
insulinratiodecreasedby10%afterad-
justment for prepregnancy adiposity but
was hardly affected by other adjustments.
The effect of maternal glucose tolerance
on fetal proinsulin concentration de-
creased by 10% after adjustment for
prepregnancy adiposity or fetal adiposity
but increased in the full adjustment
model. In contrast, the effects of prepreg-
nancy adiposity on both the fetal proin-
sulin concentration and glucose-to-
insulin ratio decreased by 20% after
adjustment for maternal glucose toler-
ance alone and by 30 and 40% for the
glucose-to-insulin ratio and proinsulin
concentration, respectively, after adjust-
ment for maternal glucose tolerance and
fetaladiposity;theassociationbecamenot
statisticallysigniﬁcantforfetalproinsulin.
The effect of fetal adiposity on cord
plasma glucose-to-insulin ratio and pro-
insulin decreased by 10% after adjust-
ment for maternal glucose tolerance and
prepregnancy adiposity but were hardly
affected by other adjustments.
CONCLUSIONS
Major ﬁndings
Tothebestofourknowledge,thisistheﬁrst
prospective pregnancy cohort study to
demonstrate that maternal glucose toler-
ance in pregnancy may affect fetal insulin
sensitivity (as indicated by the glucose-to-
insulin ratio and proinsulin concentration)
but not -cell function (as indicated by the
proinsulin-to-insulin ratio).
Maternal glucose tolerance in
pregnancy “programs” fetal insulin
sensitivity
Moststudiesoninsulinsensitivityofnew-
borns have been focused on the associa-
tion with fetal growth. Studies of
metabolic biomarkers in neonatal blood
at 2–3 postnatal days and in cord blood
presented conﬂicting evidence concern-
ing the association between insulin sensi-
tivity and fetal growth (16,17,21,22).
Very few data are available on the effects
of maternal metabolic parameters on fetal
insulin sensitivity. In a study of patients
who underwent elective cesarean section,
Catalano et al. (14) reported a strong pos-
itive correlation (r  0.35) between ma-
ternal insulin resistance at delivery and
fetalinsulinresistance.Incontrast,weob-
served a similarly strong association, but
between maternal glucose tolerance in
middle gestation and fetal insulin sensi-
tivity (r  0.31 for glucose-to-insulin
ratio, r  0.31 for proinsulin). The cord
blood glucose-to-insulin ratio was sub-
stantially lower, and the proinsulin con-
centration was much higher for infants of
mothers with gestational diabetes melli-
tus, despite similar cord blood glucose
levels, indicating adequate management
of diabetes. More importantly, we ob-
served markedly impaired fetal insulin
sensitivity in gestational diabetes mellitus
independentofmaternalandfetaladipos-
ity, family history of diabetes, gestational
age, and other potential confounders. In
addition, the observed moderate positive
correlation between ﬁrst trimester ran-
dom blood glucose and cord blood pro-
insulin concentrations suggests that
Table 3—Regression coefﬁcients (95% CI) for the associations of maternal glucose tolerance (glucose concentration at the OGTT), prepreg-
nancy adiposity (BMI), and fetal adiposity (ponderal index) with cord blood glucose-to-insulin ratio and proinsulin concentration
Cord blood glucose-
to-insulin ratio P value
Cord blood
proinsulin (pmol/l) P value
OGTT glucose, per SD (30 mg/dl ) increase
Crude 6.1 (8.8 to 3.5) 0.0001 3.6 (1.9 to 5.3) 0.0001
Adjusting for prepregnancy BMI 5.5 (8.1 to 2.9) 0.0001 3.4 (1.7 to 5.1) 0.0001
Further adjusting for fetal PI 5.3 (8.0 to 2.6) 0.0002 3.0 (1.3 to 4.7) 0.0005
Full adjustment* 5.3 (8.3 to 2.3) 0.0006 4.1 (2.3 to 6.0) 0.0001
Prepregnancy BMI, per SD (5 units) increase
Crude 4.7 (7.4 to 2.1) 0.02 2.0 (0.3 to 3.7) 0.02
Adjusting for OGTT glucose 3.8 (6.5 to 1.2) 0.005 1.5 (0.2 to 3.1) 0.09
Further adjusting for fetal PI 3.3 (5.9 to 0.7) 0.01 1.2 (0.5 to 2.8) 0.16
Full adjustment* 3.2 (6.1 to 0.3) 0.03 1.3 (0.4 to 3.1) 0.14
Infant PI, per SD (2.8 units) increase
Crude 5.6 (8.2 to 2.9) 0.0002 3.2 (1.5 to 4.9) 0.0002
Adjusting for OGTT glucose 5.2 (7.8 to 2.7) 0.0001 3.0 (1.4 to 4.6) 0.0004
Further adjusting for prepregnancy BMI 4.9 (7.5 to 2.4) 0.0002 2.9 (1.3 to 4.5) 0.0005
Full adjustment* 5.0 (7.8 to 2.3) 0.0004 2.7 (0.9 to 4.4) 0.003
n  248 mother-infant pairs. OGTT  50 g, 1-h OGTT at 24–28 weeks of gestational age; PI, ponderal index (kilograms per cubic meter). *Variables in the full
adjustment models included OGTT glucose concentration, prepregnancy BMI, maternal ethnicity, age, parity, smoking, alcohol use, family history of diabetes,
weightgaininpregnancy(SDscore),gestationalhypertensivecomplications,bacterialvaginosisandotherminorinfections,modeofdelivery,maternalglucose(5%
dextrose)intravenouslyduringdelivery,infantsex,gestationalage(weeks),birthweight(SDscore),andponderalindex(SDscore).Theadjustedresultsweresimilar
in subgroups with or without maternal glucose intravenous infusion during delivery and among boys and girls (data not shown).
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pregnancy may inﬂuence fetal metabolic
function. Taken together, our data sug-
gest a mother-baby metabolic program-
ming cycle: maternal glucose intolerance
impairs fetal insulin sensitivity and hence
programs the vulnerability to the meta-
bolic syndrome; when these female off-
spring become mothers, they are more
likely to be glucose intolerant and in turn
program more babies to be susceptible to
the metabolic syndrome. To break such a
metabolic programming cycle, it would
beimportanttoimprovematernalglucose
tolerance during early and middle preg-
nancy periods.
For patients with impaired glucose
tolerance not meeting the criteria for the
diagnosis of gestational diabetes mellitus,
we observed mild negative alterations
(not statistically signiﬁcant) in fetal meta-
bolic parameters. This ﬁnding may be ex-
plained by the limited power of our study
to detect small differences. In the large
pregnancy cohort study of patients with-
out overt diabetes in pregnancy (n 
23,316), the Hyperglycemia and Preg-
nancy Outcomes (HAPO) study group
observed a continuous association be-
tween maternal glucose tolerance at
24–32 weeks of gestation and cord blood
C-peptidelevels(12),indicatingthatmild
glucose intolerance may affect fetal meta-
bolicfunction.Thestudydidnotevaluate
fetal insulin sensitivity. Gestational glu-
cose tolerance even within normal ranges
hasbeenassociatedwiththeriskoftype2
diabetes in young Pima Indian offspring
(23).
Maternal glucose tolerance and
maternal and fetal adiposity
Our data conﬁrm the recent ﬁnding of
Catalano et al. (14) that maternal adipos-
ity may affect fetal insulin sensitivity. In
addition, we found that the effects of ma-
ternal obesity could be largely mediated
by maternal glucose tolerance and fetal
adiposity. The effects of maternal glucose
tolerance on fetal insulin sensitivity were
much stronger than those of maternal ad-
iposity and independent of a genetic in-
ﬂuence (as indicated by family history of
diabetes) and other potential confound-
ers. To a lesser extent, the effects of ma-
ternal glucose tolerance could be partly
explained by fetal adiposity.
Strengths, weaknesses, and future
research directions
Our prospective cohort design and timely
collection and processing of cord blood
specimensproviderelativelyrobustdataon
the relationships between maternal and fe-
tal metabolic parameters. Common stan-
dard protocols for assessing insulin
sensitivity (e.g., euglycemic insulin clamp)
are difﬁcult or impractical to implement
and have not been validated for newborns.
To avoid interference with routine patient
care, we took convenient cord blood sam-
ples. The newborns were not in a uniform
metabolic state; therefore, we did not use
the homeostasis model assessment of fetal
insulin sensitivity and -cell function. The
nonuniform metabolic state would have in-
creased the noise variations in our “crude”
surrogateinsulinsensitivityand-cellfunc-
tionindicatorsandhenceattenuatedtheob-
served associations. However, fasting may
be not a reliable option for assessing insulin
sensitivity in newborns as it is in adults, be-
cause neonates of diabetic mothers tend to
develop neonatal hypoglycemia after the
delivery. Furthermore, insulin sensitivity
primarily reﬂects peripheral insulin resis-
tance in newborns in contrast to hepatic in-
sulin resistance in adults (24). There is a
need for studies on the validity of various
insulin sensitivity and -cell function indi-
cators for newborns. Future studies may
examine differences in other metabolic
biomarkersandfollowuponwhetherthese
fetal metabolic changes persist in postnatal
life or predict components of the metabolic
syndrome in childhood, adolescence, and
adulthood.
In summary, our data provide some
evidence of metabolic programming in
utero by maternal glucose tolerance in
pregnancy. Further research to better un-
derstand the role of the prenatal meta-
bolic environment in developmental
programming may pave the way for early
interventions to halt the increasing epi-
demic of the metabolic syndrome and
type 2 diabetes.
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